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A balance sheet describing the integrated homeostasis of
secretion, absorption, and surface movement of liquids on
pulmonary surfaces has remained elusive. It remains unclear
whether the alveolus exhibits an intra-alveolar ion/liquid trans-
port physiology orwhether it secretes ions/liquid thatmay com-
municate with airway surfaces. Studies employing isolated
human alveolar type II (AT2) cells were utilized to investigate
this question. Human AT2 cells exhibited both epithelial Na
channel-mediated Na absorption and cystic fibrosis trans-
membrane conductance regulator-mediated Cl secretion,
both significantly regulated by extracellular nucleotides. In
addition, we observed in normal AT2 cells an absence of cystic
fibrosis transmembrane conductance regulator regulation of
epithelial Na channel activity and an absence of expression/
activity of reported calcium-activated chloride channels
(TMEM16A, Bestrophin-1, ClC2, and SLC26A9), both features
strikingly different from normal airway epithelial cells. Mea-
surements of alveolar surface liquid volume revealed that normal
AT2 cells: 1) achieved an extracellular nucleotide concentra-
tion-dependent steady state alveolar surface liquid height of4
m in vitro; 2) absorbed liquidwhen the lumenwas flooded; and
3) secreted liquid when treated with UTP or forskolin or sub-
jected to cyclic compressive stresses mimicking tidal breathing.
Collectively, our studies suggest that human AT2 cells in vitro
have the capacity to absorb or secrete liquid in response to local
alveolar conditions.
The thin liquid layer lining the alveolar space is essential for
maintaining efficient gas exchange, surfactant homeostasis,
and defense against inhaled toxins/pathogens. Airway epithe-
lial cells actively secrete or absorb ions in response to local
stimuli to coordinately regulate the liquid layer lining airway
surfaces (1, 2). However, it remains unclear whether the alveo-
lar epithelium exhibits similar capacities and, if so, how the
physiologies of the two regions are coordinated.
The alveolar surface consists of two main cell types, alveolar
type I (AT1)2 and alveolar type II (AT2) cells. AT1 cells are large
thin cells that cover a large part of the alveolar surface area. AT2
cells are cuboidal in shape and comprise 5% of the alveolar
surface area, yet they constitute 60% of alveolar epithelial cells
(3–6). Because AT2 cells can be isolated, cultured, and studied
in vitro, they have been used in attempts to understand their
contribution to alveolar liquid balance.
AT2 cells express the Na and Cl transport pathways
required to mediate liquid homeostasis on the alveolar sur-
face. Na uptake occurs at the apical surface of rat AT2 cells
in large part through the amiloride-sensitive epithelial Na
channel (ENaC) (7–9), and in situ hybridization studies have
identified the presence of mRNA for all three subunits of
ENaC in rat alveolar cells (8, 9). Na entering via ENaC is
pumped out of the cell into the interstitium by the ouabain-
sensitive Na,K-ATPase pump (7, 10). In vitro Ussing
chamber studies have identified ENaC-mediated Na ab-
sorption across rat AT2 cell monolayers, and amiloride-sen-
sitive whole lung liquid absorption has been detected in sev-
eral species in vivo (11, 12).
Although numerous studies have established active Na
transport as a major pathway for regulating liquid transport
across the alveolar epithelium, the role of Cl transport path-
ways, involving the cystic fibrosis transmembrane conductance
regulator (CFTR), is unresolved. AT2 cells express CFTR
mRNA, protein, and channels (13–15). Experiments in wild-
type mice and the ex vivo human lungs demonstrated that
liquid absorption was inhibited by glibenclamide, suggesting
a role for CFTR-dependent Cl absorption (13, 14). More-
over, both liquid absorption and Cl uptake from the distal
airspace were stimulated by -agonists in wild-type mice but
not in F508 CFTR mutant mice (16). In contrast, evidence
for alveolar liquid secretion was demonstrated by confocal
microscopy in mice, which was blunted by the CFTR inhib-
itor (CFTRinh-172) and was absent in CFTR(/) mice, sug-
gesting that the murine alveolar epithelium secrete liquid via
CFTR. Thus, a challenge remains to understand the relative
roles of CFTR-mediated Cl absorption versus secretion
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Coordinate regulation of Na absorption and Cl secretion
in airway epithelia is mediated in part via the concentrations of
nucleotides/nucleosides in the luminal extracellular compart-
ment (17). For example, ATPmediates regulatory responses via
P2Y2 receptor stimulation, and ATP metabolism provides a
source of adenosine for stimulation of the A2b adenosine recep-
tor (18–20). Recently, the mechanical stresses associated with
tidal breathing have been shown to stimulate luminal nucleo-
tide release from airway epithelial cells, providing a link
between local stresses and regulation of airway surface liquid
(ASL) volume (21). Similarly, purinergic signalingmay contrib-
ute to the integrated control of ion/liquid homeostasis within
the alveolar space. Nucleotide receptors and adenosine recep-
tors (12, 22) have been identified in mouse and rat AT2 cells,
and ATP or UTP has been reported to regulate Na and Cl
transport in cultured rat AT2 cells (23, 24). Whether a role for
nucleotide release in response to the mechanical stresses of
tidal breathing plays a role in regulating human alveolar liquid
homeostasis is as yet unknown.
In this study, we investigated the regulation of alveolar sur-
face liquid (AvSL) volume, utilizing in vitro techniques. First,
we identified the pathways that mediate Na absorption and
Cl secretion with electrophysiologic techniques in cultured
normal human AT2 cells. Second, we studied the integrated
functions of ion transport via measuring the volume of the
AvSL produced by cultured normal human AT2 cells under
basal and stimulated conditions with confocal microscopy.
EXPERIMENTAL PROCEDURES
Alveolar Type II Cell Isolation—Normal lungs rejected for
transplant by local and distant organ procurement agencies
received by the University of North Carolina Cystic Fibrosis
Center Tissue Culture Core were studied following protocols
approved by the University of North Carolina Institutional
Review Board. Human AT2 cells were isolated as previously
described with slight modifications (25). The right middle lobe
was selected, cannulated through the main stem bronchus, and
removed from the rest of the lung. The distal airspaces were
lavaged 10 times using a Ca2- and Mg2-free solution con-
taining 0.5mMEGTA (Sigma), 140mMNaCl (Fisher), 5mMKCl
(Sigma), 2.5mMNa2HPO4 (Fisher), 10mMHEPES (Sigma), and
6 mM glucose (Sigma) and then lavaged three times using the
solution above with no glucose but adding 2.0 mM CaCl2
(Sigma) and 1.3 mM MgSO4 (Sigma). Elastase (Worthington,
Lakewood, NJ), 13 units/ml in the Ca2- andMg2-containing
solution above, was instilled into the distal airspaces, and the
lobe was incubated at 37 °C for 45min. Following digestion, the
lobe was minced finely in the presence of 5% FBS (Atlanta Bio-
logical, Lawrenceville, GA) and DNase (Sigma) at 500 g/ml.
The suspension was filtered sequentially through two layers of
sterile gauze, followed by filtration through 150- and 40-m
sterile nylon meshes (Small Parts, Miramar, FL). The filtrate
was spun at 130  g for 10 min at 4 °C. The cell pellet was
resuspended in DMEM plus 10% FBS and decanted onto PBS-
and DMEM-rinsed Petri dishes coated with a human IgG anti-
body (500 g/ml in Tris buffer, pH 9.5) (Sigma) against macro-
phages for 90 min at 37 °C. The nonadherent AT2 cells were
collected, spun at 130  g for 10 min, and resuspended in
DMEM plus 10% FBS. The final AT2 suspension was seeded
on rat tail collagen I-coated (250 g/ml; Sigma) 1.12-cm2
inserts (Fisher; Corning 3460), in 5% CO2 at 37 °C at a concen-
tration of 1.0  106 cells/insert. The cells were maintained in
DMEM, 10% FBS with penicillin, streptomycin, gentamicin,
and amphotericin. For the first 5 days of culture, the medium
was supplemented with ceftazidime, tobramycin, and vanco-
mycin (all cultures). The culture medium was changed 48 h
after seeding. 72 h after isolation, the AT2 cells were washed
oncewith PBS, and culturemediumwas added only to the baso-
lateral side of the insert. All of the experiments were performed
4–9 days after seeding.
RT-PCRAnalysis—TotalRNAwasextractedusingTRIReagent
(Sigma) according to the manufacturer’s protocol for every sam-
ple. Reverse transcription was performed using 2–5 g of total
RNA, and PCRs were performed using a GeneAmp PCR System
2,700 (AppliedBiosystems,FosterCity,CA). 40cyclesofPCRwere
performed. PCRproductswere resolvedby1%agarose gel electro-
phoresis andvisualizedbyethidiumbromide staining.Theexpres-
sion of all genes of interest was normalized to that of GAPDH.
Primer sequences can be found in supplemental Table 1 (S1).
Immunofluorescence Analysis—Freshly isolated suspensions
(cytospins), cultured human AT2 cells (on rat tail type-I colla-
gen coated inserts), and mouse whole lung tissue were fixed in
4% paraformaldehyde, PBS for 5min, permeabilized using 0.1%
Triton X-100, PBS, and blocked in 2% BSA, PBS, 0.1% Triton
X-100 for 1 h. The cells were probedwith antibodies against the
precursor form of surfactant protein C (proSP-C; Chemicon,
Temecula, CA), AQP-3 (Chemicon), AQP-5 (Chemicon), or
CFTR (J. Riordan, monoclonal antibody UNC 528) in 0.1% Tri-
ton X-100, PBS for 1 h at 37 °C (or overnight at 4 °C). Negative
controls used species-specific IgG. The sample(s) were washed
three times with PBS and then incubatedwith a secondary anti-
body (Alexa-Fluor 568 goat anti-mouse/rabbit) (Invitrogen) in
0.1% Triton X-100, PBS for 1 h at 37 °C in the dark. The cell
nuclei were stained with either DAPI (Anaspec, Fremont, CA)
or SYTOX Green (Invitrogen), and the slides were washed,
mounted, and imaged using confocal microscopy.
Ion Transport Measurements—Ussing chamber studies were
performed on human AT2 cultures under basal conditions or
after the addition of designated reagents under open circuit
conditions (27). Basal potential difference (PD) and changes in
response to each added reagent were measured, and the equiv-
alent short circuit (Ieq) was calculated as previously described
(27, 28). The following agents were tested: amiloride (Sigma)
(100M, luminal); forskolin (Sigma) (10M, luminal); UTP (GE
Healthcare) (100 M, luminal); ATP (GE Healthcare) (100 M,
luminal); adenosine (Sigma) (100 M, luminal); UDP (Sigma),
(100 M, luminal); ionomycin (Sigma) (5 M, luminal); or the
CFTR inhibitor (CFTRinh-172; (10 M, luminal).
Measuring Intracellular Ca2 ([Ca2]i)—5–9-Day-old cul-
tures of normal AT2 cells were loaded with 2.5 M fura-2/AM
and basal Ca2 levels, andCa2mobilization in response to 100
M UTP followed by ionomycin (10 M) was measured by
microfluorimetry in the presence of a HEPES-buffered saline
solution containing 1.3 mM Ca2, as previously described (29,
30). The data are expressed as 340/380 (UTP-induced peak
value  base-line value) fura-2 fluorescence.
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ATP Concentration and Release Rates—Real time basal ATP
levels and release rates were performed as previously described
(31). Confluent AT2 cells with soluble luciferase (Sigma; L9506;
0.5–2.0 g/culture) and luciferin (150 M) added to the muco-
sal surface (90 l) were gently placed in the Turner TD-20/20
luminometer. Luminescence was measured every minute until
the ALU values reached steady state, the measure of basal con-
centrations. ATP release rates from resting AT2 cells were
measured by monitoring ATP accumulation in real time
after maximal inhibition of cell surface nucleotidase activi-
ties. The nucleotidase inhibitor mixture contained 300 M
,-methylene-ATP, 30 M ebselen, and 10 mM levamisole
to inhibit ecto-nucleotide pyrophosphatase/phosphodies-
terases, ecto-nucleotide triphosphate diphosphohydrolases,
and nonspecific alkaline phosphatases. After the basal ATP
concentration was recorded as described above, the inhibi-
tor mixture was added to the mucosal liquid, and ATP con-
centrations were measured every minute. In selected exper-
iments, forskolin (10 M) was added during the release
measurements. A standard curve for each experiment was
also generated using a solution of ATP (GE Healthcare;
100 mM).
Measuring AvSL Height—AT2 cultures, under air-liquid
interface conditions, were incubated with CellTraceTMCalcein
Green, AM (3 M; Invitrogen) for 20 min at 37 °C to stain live
cells. The cells were washed with PBS, followed by apical addi-
tion of Texas Red-labeled 70-kDa dextran/PBS (2.5 mg/ml;
Invitrogen) to measure AvSL height. For studies of basal AvSL
regulation, 25l of Texas Red-labeled 70-kDa dextran, dextran,
PBS, and perflurocarbon (50 l) were added, and the cells were
imaged immediately and serially for 24 h at five predetermined
sites, as previously described (32). Studies of forskolin or UTP
were performed by incubating 25 l of Texas Red-labeled
70-kDa dextran, PBS fluorophore on the cell surface for 30 min
at 37 °C, followed by removal of excess dextran to initiate stud-
ies under steady state “thin film” conditions. The images were
taken serially post-agonist addition with x-z confocal micros-
copy. In selected studies, apyrase (10 units/ml; Sigma) was
added with the 70-kDa dextran, PBS solution for studies
focused on: 1) control of basal AvSL height and 2) mechanisms
of forskolin responses. For studies designed to measure inhibi-
tion of CFTR activity, the CFTR inhibitor (CFTRinh-172) was
added to the 70-kDa dextran, PBS solution, and cultures were
incubated at 37 °C for 30 min, followed by the addition of for-
skolin or UTP.
Cyclic Compressive Stress (CCS)—25 l of the Texas Red-
labeled 70-kDa dextran, PBS fluorophore were added to the
mucosal surface of AT2 cultures, and residual liquid was aspi-
rated after 30 min, following which x-z confocal images were
obtained at 0, 1, and 24 h under control conditions or under
CCS (0–20 cmH2O), delivered by a published technique (21).
To explore the role of nucleotide release in CCS-mediated alve-
olar liquid responses, parallel AT2 cultures were treated with
apyrase (10 units/ml; Sigma) in the 70-kDa dextran, PBS fluoro-
phore for 30 min prior to the initiation of CCS.
Data Expression and Statistical Analysis—All of the experi-
ments were performed in triplicate, and the cells were obtained
from at least three different patient specimens. The data are
presented as themeans S.D., analyzed by one-way analysis of
variance, and the differences were considered significant if p 
0.05 (*) and p  0.01 (#).
RESULTS
Characterization of Freshly Isolated and Cultured AT2 Cells—
Following elastase digestion and filtration/enrichment, the
purity of the final cell preparations was determined for human
normal AT2 cells to be 91.7  2.9% as assessed by immuno-
staining for proSP-C (normal; Fig. 1A, panel i). Freshly isolated
cells also expressed other AT2 cell markers, including lamellar
bodies imaged with the fluorescent probe Lysotracker Green
DND-26 (Lysotracker) (Fig. 1A, panel ii) and aquaporin-3
(AQP-3; Fig. 1A, panel iii), which was detected immunocyto-
chemically. In contrast, preparations were negative for the AT1
cell marker aquaporin-5 (AQP-5; Fig. 1A, panel iv) (33), as
assessed by immunostaining. CFTR protein was detected in
freshly isolated normal AT2 preparations by immunostaining/
confocal microscopy (Fig. 1A, panel v).
Normal human AT2 cells were seeded on rat tail type 1 col-
lagen-coated polycarbonate filters and formed confluent
monolayers within 96 h after seeding. Transepithelial resis-
FIGURE 1. Characterization of human AT2 cells. A, the purity of freshly iso-
lated normal human AT2 cells (panel i) was determined by immunostaining
using a proSP-C antibody. Freshly isolated normal AT2 cells were also probed
using Lysotracker Green DND-26 (panel ii), antibodies probing for AQP-3
(panel iii), AQP-5 (panel iv), or CFTR (panel v) protein expression to assess AT2
purity. B, normal human AT2 cells were cultured in DMEM  5% FBS medium
on rat tail collagen-1-coated 1.12-cm2 membrane Transwell inserts and
exposed to air-liquid interface 96 h post-seeding. Differential interference
contrast (panel i, 20 objective), Lysotracker (panel ii), and proSP-C (panel iii)
imaging were performed to assess the purity of AT2 cultures 5 days after
seeding by confocal microscopy. Normal human AT2 cells 14 days in culture
were probed using Lysotracker (panel iv), proSP-C (panel v), or AQP-5 (panel
vi) to assess the trans-differentiation process of AT2 cells in culture over time
into AT1-like cells (arrows indicate positive cells). C, mRNA from freshly iso-
lated human AT2 cells, as well as mRNA from cells 4 –14 days post-seeding,
were collected. SP-C gene expression was measured using semi-quantitative
PCR. D, semi-quantitated PCR was also measured for SP-A, AQP-3, and AQP-5
gene expression in normal AT2 cultures 5 or 14 days after seeding to charac-
terize cell phenotype. All of the original images were taken using a 63 objec-
tive, unless otherwise stated.
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tance was 419.3 	*cm2  168.1 at day 5 in culture (n 
 3
different patient specimen codes). At day 5, the AT2 cell mono-
layers retained AT2-like features, as indexed by differential
interference contrast microscopy (Fig. 1B, panel i), Lysotracker
(Fig. 1B, panel ii), and proSP-C (Fig. 1B, panel iii) antibody
immunostaining. To address the possibility that AT2 cells
trans-differentiated in culture over time to an “AT1-like” cell
phenotype, AT2 cells were probed over 14 days in culture with
Lysotracker (Fig. 1B, panel iv), proSP-C (Fig. 1B, panel v), and
AQP-5 antibodies (Fig. 1B, panel vi) and imaged by confocal
microscopy. Cultures lost significant expression of the Lyso-
tracker and pro-SPC with time. In contrast, AQP-5 expression
increased, supporting the concept that AT2 trans-differentia-
tion into AT1-like cells in culture has occurred by day 14.
Human AT2 mRNA was isolated from fresh preparations
and cells 2–14 days in culture, and RT-PCR was performed to
characterize the expression of SP-CmRNA over time (Fig. 1C).
Expression of SP-C decreased with time in culture. SP-A,
AQP-3, and AQP-5 mRNA was analyzed at 5 and 14 days in
culture by RT-PCR to more fully characterize the AT2 culture
phenotype (Fig. 1D). Overall, these studies confirmed the
reduction of AT2 markers (SP-A, SP-C, and AQP-3) and
revealed the appearance of an AT1 marker (AQP-5) over time
in our cultures. Therefore, all of the experiments within this
study were performed on AT2 cultures 4–9 days after seeding.
Na Transport by AT2 Cells—To identify which sodium
channels/subunits were expressed in human AT2 cells, semi-
quantitative PCR analysis was performed on mRNA from
freshly isolated and AT2 cells 5 or
14 days in culture. The , , and 
subunits of ENaC were expressed
at all time points; however, no
expression of the  subunit was
detected (Fig. 2A). With respect to
other electrogenic Na transporters,
expression of the glucose-sodium
transporter-2 (GLUT2/SLC2A2) was
detected but not the glucose-sodium
transporter-1 (GLUT1/SLC2A1)
gene. In addition, mRNA expres-
sion of the -cyclic nucleotide-
gated Na channels (-CNG1–3)
was detected, but no expression
was observed of the -CNG1 in
AT2 cultures. Bioelectric measure-
ments of normal and CF AT2 cul-
tures revealed small inhibitory
responses (5%) to the glucose-so-
dium transporter inhibitor (phlo-
ridzin) or the cyclic nucleotide-
gated sodium channel inhibitor
(diltiazem) (5%), suggesting that
Na transport in human AT2 cells
is primarily mediated by ENaC.
Therefore, we initiated experiments
to further characterize ENaC-medi-
ated Na absorption in human AT2
cultures.
To measure basal ENaC-mediated Na absorption, normal
humanAT2 cells were treated with amiloride (100M), and the
change in PD was measured (Fig. 2B). The basal equivalent
short circuit current (Ieq) and the post-amiloride-sensitive
Ieq values were 7.69  1.9 and 3.11  0.52 A/cm2, respec-
tively (Fig. 2C), suggesting that Na absorption (amiloride
Ieq  4.58 A/cm2) is the dominant basal ion transport pro-
cess. An amiloride dose-response curve for normal AT2 cul-
tures revealed an IC50 of 5  107 M (Fig. 2D).
Because agents that raise cellular cAMP levels increase Na
absorptive rates in mouse and rat AT2 cells (34), similar proto-
cols were performed in human AT2 cells. Normal human AT2
cultures exposed to forskolin (10 M) exhibited a rapid spike,
followed by a slow gradual increase in PD that was inhibited by
amiloride (Fig. 2E). Themean increase inNa absorption stim-
ulated by forskolin was 6 Acm2.
Cl Secretion by AT2 Cells—We first characterized cAMP-
regulated/CFTR-mediated Cl secretion in AT2 cells in Ussing
chambers. Normal human AT2 cultures were treated with
CFTRinh-172 (10 M), a CFTR inhibitor (35), to measure the
contribution of CFTR to basal Ieq, followed by exposure to
amiloride (Fig. 3A). The change in Ieq in response to CFTRinh-
172 was small, 0.4 A/cm2, suggesting that normal AT2 cells
exhibit only a small rate ofCFTR-mediatedCl secretion under
basal conditions (Fig. 3B). To assess the capacity of CFTR to
accelerate Cl secretion, human normal AT2 cultures were
treated with forskolin in the presence of amiloride. Forskolin
induced a rapid increase in the potential difference in AT2 cul-
FIGURE 2. Na transport properties of human AT2 cells. A, semi-quantitative PCR analysis was performed to
identify the expression of genes whose products could mediate electrogenic Na absorption in freshly isolated
or cultured human AT2 cells. B, normal AT2 cultures were mounted in Ussing chambers, transepithelial electric
PDs measured under open circuit conditions, with response to amiloride (100 M, luminal). C, basal and amilo-
ride-sensitive equivalent short circuit currents (Ieq) were measured in normal AT2 cultures mounted in Ussing
chambers (means  S.D.; n  6; *, p  0.05). D, an amiloride dose-response curve was generated in normal AT2
cultures (mean  S.D.; n  3). E, the potential difference (mV) and the change in equivalent short circuit current
(Ieq) were measured after exposure to forskolin (10 M) followed by treatment with amiloride (100 M, lumi-
nal) in normal AT2 cultures (n  6).
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tures (Fig. 3C), consistent with anion (Cl) secretion. The acute
anion secretory effects of forskolinwere significantly blocked in
normal AT2 cells pretreatedwithCFTRinh-172 (Fig. 3D). These
results suggest that forskolin-stimulated Cl secretion in
amiloride-pretreated normal AT2 cells is predominantly medi-
ated via CFTR.
We next measured [Ca2]i-regulated Cl secretion in
human AT2 cells. There was little change in basal Ieq in re-
sponse to putative Ca2-activated chloride channel (CaCC)
antagonists, e.g. DIDS or niflumic acid (data not shown).
Increases in Ieq were observed when normal AT2 cultures
were treated with the Ca2 ionophore, ionomycin, in the
presence of amiloride (Fig. 4A). DIDS or niflumic acid (gen-
eral inhibitors of Ca2-activated chloride channels) did not
block the ionomycin-induced currents in normal AT2 cul-
tures (data not shown). Surprisingly, the acute response to
ionomycin was significantly inhibited in normal AT2 cul-
tures pretreated with CFTRinh-172 (Fig. 4A). These data
indicate that CFTR mediates [Ca2]i-regulated anion secre-
tion in normal human AT2 cells.
We performed two further sets of experiments to explore the
hypothesis that CFTR indeed mediated Ca2-regulated chlo-
ride secretion. First, we confirmed that ionomycin indeed
raised intracellular Ca2 ([Ca2]i) similarly in normal human
AT2 cells (Fig. 4B). Second, we performed semi-quantitative
PCR analysis in freshly isolated, day 5 and 14 AT2 cells to iden-
tify expression of candidate Ca2-regulated Cl channels (Fig.
4C). CFTR was expressed, but no mRNA expression of
TMEM16A, CLC2, or SLC26A9 was detected in AT2 cells.
Moreover, no full-length Bestrophin-1 mRNA expression was
detected. Collectively, these data suggest that AT2 cells secrete
Cl via CFTR in response to [Ca2]i signaling in the absence of
known CaCC channel expression.
Extracellular Nucleotide-dependent Regulation of Ion Trans-
port in AT2 Cells—Luminal extracellular mediators, e.g.
triphosphate nucleotides (UTP or ATP) and the adenine nucle-
oside, adenosine, have been shown to inhibitNa transport and
accelerate Cl secretion in normal airway epithelial cells (17).
To test whether a similar physiology exists in the alveolar epi-
thelium, normal human AT2 cultures were exposed to UTP
(100 M, luminal) under basal conditions. A rapid increase in
PD was observed followed by a small consistent later reduction
in PD (Fig. 5A). Ieq analyses revealed that UTP stimulated an
approximate 17 A/cm2 increase in current that reflected
anion (Cl) secretion (Fig. 5B, UTP (early)), followed by an
inhibition of Ieq, likely reflecting inhibition of Na absorption
(Fig. 5B, UTP (late)).
Next, we exposed humanAT2 cells toUTP in the presence of
amiloride (Fig. 5C). The increase in Ieq was 20 A/cm2. Sim-
ilar to ionomycin, the UTP-stimulated Cl secretion in normal
AT2 cells was significantly reduced in the presence of CFTRinh-
172 (Fig. 5,D andE). Aswith ionomycin, we verifiedwith fura-2
measurements that UTP raised intracellular Ca2. These data
suggest that the nucleotide-regulated anion secretion reflects
Ca2 activation of CFTR.
We next characterized the relative efficacy for Cl secretion
of purinoceptor agonists by exposing normal AT2 cultures to
ATP, adenosine, or UDP in the presence of amiloride (Fig. 5G).
Although all agonists stimulated increases inIeq, the response
to ATPwas smaller when compared with UTP (Fig. 5, compare
E and G). The UDP and adenosine responses were both small
relative to UTP/ATP.
FIGURE 3. Cl transport properties of human AT2 cells. A, normal human
AT2 cultures were studied under basal conditions and after exposure to the
CFTR inhibitor (CFTRinh-172, 10 M) followed by the addition of amiloride
(100 M) in Ussing chambers. B, equivalent short circuit currents (Ieq) in nor-
mal AT2 cells under basal versus post-CFTRinh-172 addition are summarized
(means  S.D.; n  6). C, Ussing chamber studies were performed to measure
the forskolin-mediated secretory capacity of normal AT2 cultures in the pres-
ence of amiloride. D, the change in the equivalent short circuit current
(Ieq) induced by forskolin in normal AT2 cultures, with or without CFTRinh-
172 (10 M) (mean  S.D.; n  6; *, p  0).
FIGURE 4. Calcium-mediated Cl secretion in human AT2 cells. A, the
changes in equivalent short circuit currents (Ieq) were measured and quan-
titated by Ussing chamber analysis in response to ionomycin (5 M, luminal)
in normal AT2 cells and normal AT2 cells pretreated with CFTRinh-172 in the
presence of amiloride (means  S.D.; n  3; *, p  0.05). B, intracellular Ca2
responses (340/380 fura-2 ratio) of fura-loaded normal AT2 cells were mea-
sured, and the responses were summarized (means  S.D.; n  3). C, semi-
quantitative PCR analysis was performed to identify chloride channel genes
(CFTR, TMEM16A, CLC2, and SLC26A9) expressed in freshly isolated or cul-
tured normal AT2 cells.
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To identify which receptors may be transducing nucleotide/
nucleoside responses, semi-quantitative PCR was performed
for nucleotide (P2Xs/P2Ys) and adenosine receptors expressed
in either freshly isolated, day 5 in culture, or day 14 post-seeding
AT2 cells. The A2aR and A2bR adenosine receptors were
expressed in freshly isolated cells and cultured AT2 cells
(Fig. 5H). P2Y2, P2Y4, and P2Y6 were all expressed in fresh
isolates, as well as within cultures seeded for 5 or 14 days (Fig.
5H). The P2X4 receptor was present throughout all time peri-
ods, whereas P2X7 was only present in freshly isolated cells.
Regulation of AvSL byAT2Cultures—We first askedwhether
AT2 cell cultures homeostatically regulated surface liquid vol-
ume in response to a liquid challenge, similar to airway epithelia
(17). Confluent live AT2 cells were stained using CelltraceTM
Calcein Green, followed by the
addition of 25l of PBS containing a
Texas Red-labeled 70-kDa dextran
fluorescent probe to the culture sur-
face. AvSL height was then quanti-
tated for 24 h by confocal micros-
copy (Fig. 6, A and B). A rapid
decrease in AvSL height was
observed after “flooding” the cul-
tures, following which a steady state
height was achieved at 4–5 m.
In airway epithelial cells, the
steady state ASL height is deter-
mined by the rates of nucleotide
release and the ASL nucleotide/nu-
cleoside concentrations that result
(18). Using the luciferin/luciferase
assay, we measured basal ATP con-
centrations in the AvSL covering
AT2 cultures and found it to be
8.0  4.2 nM (Fig. 6C). The basal
ATP concentration reflects the bal-
ance between the rate of ATP
release (891.9  300.0 fmol/cm2/
min; Fig. 6C) and ecto-metabolism
(36). To explore the role of nucleo-
tide release/basal concentrations in
regulating basal AvSL height, we
measured AvSL height in untreated
AT2 cultures versus those treated
with an enzyme, apyrase (10 units/
ml), on the apical surface that
metabolizes all nucleotides in the
local environment. Untreated nor-
mal human AT2 cultures exhibited
persistent AvSL heights of 4–5
m over 4 h, whereas cultures
treated with apical apyrase ab-
sorbed virtually all AvSL (Fig. 6, D
andE). Thus, we conclude that basal
AvSL height is dependent on AvSL
nucleotide concentrations.
We next explored mechanisms
that might regulate liquid transport
in normal AT2 cultures. To perform these experiments, we
started each protocol with a relatively thin film of AvSL to sim-
ulate in vivo conditions (Fig. 7A). In control experiments, the
residual liquid was absorbed over time, reaching a steady state
height again of 4–5 m (Fig. 7A). We first investigated the
contribution of the cAMP-releasing agent forskolin to AvSL
height regulation. Surprisingly, unlike the forskolin-mediated
increase in Na absorption observed in Ussing chambers (Fig.
2, F andH), forskolin stimulated an increase in AvSL height, i.e.
liquid secretion, within 30 min of treatment, followed by a
return to basal liquid height by 4 h (Fig. 7, A and B). To test
whether CFTR mediated the liquid secretion in response to
forskolin addition, normal AT2 cultures were pretreated with
CFTRinh-172 for 30 min followed by the addition of forskolin.
FIGURE 5. Nucleotide/nucleoside-mediated regulation of human AT2 cell ion transport. A, potential dif-
ferences were measured in normal AT2 cultures before and after exposure to UTP (100 M, luminal) in Ussing
chambers. B, the “early” and “late” responses to UTP were quantitated. Summary data describing equivalent
short circuit current (Ieq) in normal AT2 cells before and after (early/late) UTP exposure (means  S.D.; n  6; *,
p  0.05). C and D, UTP effect on potential differences in amiloride-pretreated normal AT2 cultures (C) and
normal AT2 cultures treated with CFTRinh-172 (D). E, changes in equivalent short circuit current for UTP
responses without and with CFTRinh-172 pretreatment conditions (means  S.D.; n  6; #, p  0.01). F, Ca
2
mobilization (340/380 fura-2 ratio) was measured in normal AT2 cultures following the addition of UTP (100
M, luminal). G, ATP (100 M), adenosine (100 M), or UDP (100 M) was added apically to normal AT2 cultures,
and Ieq was measured and summarized (mean  S.D.; n  3). H, semi-quantitative PCR analysis to identify
gene expression of nucleotide/nucleoside purinergic receptors present in normal AT2 cells freshly isolated and
over time in culture.
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The forskolin-induced increase in AvSL height was signifi-
cantly reduced in the presence of CFTRinh-172 (Fig. 7B). These
findings suggest that forskolin-induced liquid secretion is
highly CFTR-dependent in human AT2 cells.
The disparity in the directionality of responses to forskolin in
AT2 cultures in the Ussing chamber (absorption) versus confo-
cal measurements (secretion) likely reflects differences in the
conditions of the two assays. The Ussing chamber’s large bath-
ing volumes “dilute” signals within AvSL (e.g. nucleotides) that
accumulate within the thin film liquid conditions reprised in
the confocal technique. For forskolin to elicit secretion under
thin film conditions, such “signals” in AvSL would need to
inhibit ENaC sufficiently to generate an electrochemical gradi-
ent for Cl secretion and block forskolin-mediated ENaC acti-
vation. Candidate endogenous signals that inhibit ENaC are the
tri-phosphate nucleotides, e.g. ATP or UTP.
Direct measurements of ATP on the apical surface of AT2
cells suggested that the basal concentrationwas8 nM. It is not
clear that this concentration alone is sufficient to inhibit ENaC
and generate the driving forces for forskolin-dependent Cl/
liquid secretion. Therefore, we speculated that forskolin may
also stimulate nucleotide release (ATP) to further inhibit ENaC
andpromote a secretory response.Measurements that detected
an increase in ATP release rates induced by forskolin were con-
sistent with this notion (Fig. 7C).
Finally, we asked whether nucleotides in AvSLwere required
to produce the forskolin-induced secretory response. To
address this question, we again used the strategy of including
apyrase in the luminal surface liquid to metabolize released
nucleotides. Importantly, pretreat-
ment of the AvSL with apyrase
markedly blunted the volume secre-
tory response to forskolin (Fig. 7, D
and E), suggesting a requirement for
nucleotides in the forskolin-medi-
ated AT2 cell secretory response.
Regulation of AvSL Height by
Cyclic Compressive Stress/Nucleo-
tide Release—Because it has been
previously shown in airway epithe-
lial cultures that ASL height is regu-
lated by mechanical stresses that
mimic normal tidal breathing (21)
via regulation of nucleotide release
rates, we asked whether a similar
physiology exists in AT2 cells. First,
the role of nucleotides in mediating
the CCS response was explored in
studies of nucleotide regulation of
AvSL volume. Luminal UTP (100
M) addition stimulated AT2 cell
liquid secretion within 30 min,
returning to the basal 4–5-m
height within the 4-h observational
interval (Fig. 8A). Similar to forsko-
lin, the rapid UTP volume secretory
response was significantly blocked
by pretreatment with CFTRinh-172
(Fig. 8B). Second, AT2 cultures were subjected to CCS for 24 h,
and the change in AvSL height was measured. Normal AT2
cultures demonstrated a significant increase in AvSL height 3 h
after exposure to CCS, and the AvSL height was increased fur-
ther at 24 h of continuous CCS exposure (Fig. 8C), demonstrat-
ing that CCS stimulated liquid secretion in AT2 cultures. AvSL
liquid secretion was markedly inhibited in cultures pretreated
with apyrase (Fig. 8D), demonstrating a nucleotide-mediated
regulation of AvSL height under CCS conditions.
DISCUSSION
A balance sheet describing the integrated homeostasis of
secretion, absorption, and surface movement of liquids on pul-
monary surfaces has remained elusive. Whereas it is clear that
liquids move cephalad along airway surfaces via the actions of
cilia and potentially gas-liquid pumping (2), the origin of airway
surface liquids is unclear. Two sites of secretion appear plausi-
ble. First, it is possible that secretions are formed by active ion
transportmechanisms on distal small airway surfaces, although
studies of ion transport gene expression and function do not
support such a notion (37–39). Alternatively, active ion secre-
tion by alveolar surfaces could mediate liquid secretion with
movement of secreted liquids onto small airway surfaces. How-
ever, despite some recent evidence for this latter notion (16, 40),
the prevailing concept has been that the alveolus is primarily
absorptive (41–43).
The ideal approach to this question is to study the intact
alveolar epithelium; however, this approach is difficult because
of the anatomy of the airway. Although it is likely that AT1 cells
FIGURE 6. Regulation of basal AvSL height by normal human AT2 cultures. Live human AT2 cells were
labeled with Calcein Green, and then the AvSL was labeled with a Texas Red-labeled 70-kDa dextran fluoro-
phore. A, AvSL height was measured serially after the addition of the Texas Red-labeled 70-kDa dextran fluoro-
phore (25 l) by confocal microscopy. B, the mean changes in AvSL height were measured and plotted over
24 h. C, luminal extracellular ATP levels were measured in normal AT2 cultures using the luciferase/luciferin
assay in the absence (basal levels) and presence of ATPase inhibitors (measure of ATP release rate). D, AvSL
height was imaged by confocal microscopy over 4 h in the absence or presence of apyrase (10 units/ml). E, AvSL
height was quantitated at 4 h before and after apyrase treatment (mean  S.D.; n  3; *, p  0.05). All of the
original images were z scans taken using a 63 objective. All of the scale bars represent 5 m.
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have the capacity and machinery for active ion transport, cur-
rently no AT1-derived cell culture model has been successfully
developed to study ion/liquid transport properties on a conflu-
ent AT1 monolayer. Therefore, like others, we focused on
studying this question in isolated and cultured human AT2
cells. Our data suggest that they form moderate resistance
(400 	*cm2) monolayers with basal short circuit currents of
7 A/cm2. Approximately 60% of the basal current was sen-
sitive to the Na transport inhibitor amiloride. Less than 5% of
basal Isc was sensitive to the inhibitor of CFTR-mediated Cl
secretion, CFTRinh-172. Thus, basal ion transport of human
AT2 cells in Ussing chambers, in which the lumen is flooded
and endogenous surface liquid signals/regulators are diluted, is
dominated by Na absorption.
We next studied the mechanisms mediating Na transport
in cultured human AT2 cells. As noted above, Na absorption
was inhibited by the ENaCblocker, amiloride, with aKi of5
107 M (Fig. 2D). The subunit composition of ENaCdetermines
the amiloride Ki and can vary among tissues. Our data, with
respect to ENaC subunit mRNA expression in AT2 cells, sug-
gest that ENaC is comprised potentially of,, andENaC, but
not  ENaC (Fig. 2A). The amiloride Ki for Na transport inhi-
bition by amiloride in AT2 cells is shifted by approximately 1
order of magnitude to the right from that reported for , , and
 channels expressed heterologously in oocytes (44). ENaC
channels composed of ENaC
subunits or  subunits expressed
in oocytes exhibit amiloride Ki val-
ues similarly shifted to the right (7).
Thus, it is possible that Na trans-
port in AT2 cells is mediated by a
combination of ENaCchannelswith
different stoichiometries, e.g. 
and , as has been suggested by
the patch clamp data of Eaton et al.
(7). Note that we found relatively
little evidence for a large contribu-
tion of other Na transport pro-
cesses to AT2 cell Na transport,
including electrogenic Na-glucose
transport, Na-amino acid trans-
port, or cyclic nucleotide-gated cat-
ion channel-mediated transport.
The regulation of Na transport
rates in normal AT2 cells appears
to be quite distinct from that in air-
way epithelial cells. For example,
the addition of agents that raise
intracellular cAMP, e.g. forskolin,
raised Na transport rates in nor-
mal AT2 cells (45) (Fig. 2E), whereas
these agents inhibit Na transport
in airway epithelial cells (46). The
cAMP-dependent inhibition of
ENaC activity in airway epithelia
has been attributed to CFTR, based
on studies in heterologous cells that
demonstrated cAMP-dependent,
CFTR-mediated inhibition of ENaC (47–49). Thus, the obser-
vation that forskolin raises AT2 cell Na transport rates in nor-
mal AT2 cells suggests that CFTR does not have an inhibitory
role in ENaC function in this cell type.
With respect to Cl transport, airway Cl secretion is dom-
inated in the submucosal gland acini by CaCC activities,
whereas in the superficial epitheliumCl transport is mediated
by bothCFTRandCaCC (50, 51). In striking contrast, it appears
that CFTR is the principal Cl channelmediatingCl secretion
in normal human AT2 cells, with little evidence for CaCC
expression/function. For example, agents that raise intracellu-
lar cAMP, e.g. forskolin, activated normal AT2 cell anion secre-
tory currents that were inhibited by CFTRinh-172. Ionomycin
(Fig. 4, A and B) or luminal nucleotides (Fig. 5C), e.g. ATP or
UTP, also activated Cl secretory currents in normal AT2 cells.
However, in contrast to airway cells, the stimulated secretory
currents were inhibited by CFTRinh-172, implying that they
were mediated by CFTR and not CaCC. The failure of ionomy-
cin or UTP to activate CaCC was not due to failure to raise
[Ca2]i, as evidenced by the large [Ca2]i responses to ionomy-
cin or UTP (Figs. 4B and 5F). Indeed, our data suggest that the
failure to activate CaCC-mediated currents by ionomycin or
UTP reflects the virtual absence of expression of some known
CaCC channels in human AT2 cells, including TMEM16A,
ClC2, SLC26A9, and Bestrophin-1 (Fig. 4C).
FIGURE 7. Regulation of AvSL height by forskolin by normal human AT2 cultures. Normal human AT2 cells
were labeled with Calcein Green, and AvSL was labeled with 25 l of Texas Red-labeled 70-kDa dextran fluoro-
phore for 30 min prior to aspiration. A, control and post-forskolin AvSL height starting from basal thin film
conditions were imaged by confocal microscopy in confluent normal AT2 cultures over 8 h. B, confluent normal
AT2 cultures were treated without (control) or with forskolin, in the absence or presence of CFTRinh-172, and
AvSL height was measured over 8 h (mean  S.D.; n  3; *, p  0.05 different from control; †, p  0.05 different
from forskolin (Fsk) treatment). C, luminal ATP release rates were measured before and after exposure to
forskolin (10 M) in the continued presence of ATPase inhibitors. D, confocal images showing control, forskolin
(10 M), and apyrase (10 units/ml)/forskolin-treated normal AT2 cells. E, summary data plotting AvSL height
versus time in control, forskolin-treated, and apyrase/forskolin-treated normal AT2 cultures (means  S.D.; n 
3; *, p  0.05 different from control; †, p  0.05 different from forskolin treatment). All of the scale bars represent
5 m.
Regulation of Ion/Liquid Transport in Alveolar Type II Cells
34946 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 45 • NOVEMBER 5, 2010
The observation that CFTR is the principal anion channel in
the apical membrane of human AT2 cells raises two questions.
First, if nucleotides do not regulate CaCC by Ca2 signaling,
howdo they regulateCFTRactivity? It is possible that the raised
Ca2 levels associated with nucleotide receptor activation cou-
ple with diacylglycerol formation and adenyl cyclases activate
PKC and CFTR (52, 53). However, it should also be noted that
Kunzelmann and co-workers (54) recently suggested a non-
PKC-dependentmechanism for nucleotide regulation of CFTR
via as-yet-unknown protein phosphatase(s). The second im-
portant question is, why do CF patients not experience more
alveolar disease, if indeed CFTR is the sole anion channel in
the apical membrane of CF cells? The answer to this question
will await a more complete characterization of potential other
anion channels inCF cells and further elucidation of the normal
ion/liquid transport physiology of the alveolus in vivo.
A series of studies have demonstrated the importance of
nucleotide/nucleoside concentrations in airway surface liquid
in directing the relative rates of absorption versus secretion
across human airway epithelial barriers (17, 21). A complex but
somewhat different physiology is evident in our studies of AT2
transport function. For example, nucleotides exhibit the capac-
ity to inhibit ENaC activity and, as noted above, also to acceler-
ate anion secretion. Nucleotide regulation of K secretion is
likely aswell but is not investigated in these studies. As reported
for alveolar epithelia from rat, a large number of purinoceptors
are potentially expressed on the apical membrane of human
AT2 cells. Like airways, the P2Y2-R triphosphate nucleotide
receptor (recognizing ATP and UTP) and the UDP liganded
P2Y6 receptor, are expressed and appear functional in human
AT2 cells. Of note, the anion secretion activated byUTP (Fig. 5,
C and E) is larger than that activated by ATP (Fig. 5G) in AT2
cells. This observation suggests that theUTP selective P2Y4 and
not the ATP-ligand P2X4 or P2Y2 receptors may be the domi-
nant nucleotide receptor on the apical membrane of AT2 cells.
Of note,Matalon and co-workers (55) have suggested inmouse
models that the release of UTP in the distal lung in response to
viral infection can produce a secretory pulmonary edema.
Finally, in the presence of amiloride, adenosine was active in
initiating anion secretion, likely through an A2b receptor, but
this secretion is smaller than activated by triphosphate nucleo-
tides. Again,Matalon and co-workers (12) have suggested a role
for adenosine in mediating secretion in the murine alveolus.
It has been difficult to achieve a unified understanding of the
surface liquid physiology of the intact alveolus. A first study to
explore AT2 liquid homeostatic capabilities with the confocal
microscopy technique was to place a small volume of liquid on
the AT2 culture surface and observe how the epithelium
responded to this challenge. As shown in Fig. 6A, when theAT2
cell surface was effectively flooded by this maneuver, the AT2
cells absorbed the added liquid over a 2–4-h period, following
which AT2 cells appeared to balance absorption and secretion
to maintain a steady state surface liquid height of 4–5 m.
This simple experiment has two implications. First, it
appears that when signals that are contained within the AT2
cell surface liquid are diluted by exogenous liquid addition, the
AT2 cells revert to an absorptive mode. These data are consis-
tent both with a response of human airway epithelial culture to
similar maneuvers and, indeed, with observations that the
mammalian alveolus in vivo, when flooded, exhibits a volume-
absorptive phenotype (41, 56, 57). Second, the AT2 cell prepa-
rations generated a steady state surface liquid height of 4–5
m. In airway epithelia devoid of cilia, an airway surface liquid
height of 4–5min steady state is alsomaintained, in large part
reflecting the rate ATP secretion and ATP/ADO regulation
of Na versusCl transport to achieve a homeostatic surface
liquid level (17). Our data reveal that AT2 cell monolayers: 1)
release ATP at a rate somewhat greater than airway epithe-
lial cells (800 fmol/cm2/min versus 300 fmol/cm2/min (31)
(Fig. 6C)); 2) produce a resting AvSL ATP concentration (8
nM) somewhat higher than airway epithelia (Fig. 6C); and 3)
cannot maintain a basal AvSL height/volume in the presence
of apyrase (Fig. 6, D and E), arguing that the basal AvSL
height is, like airway epithelial cells, determined by nucleo-
tide release/signaling.
We also employed the confocal technique to ask how AT2
cell monolayers regulate volume in response to the prototypic
regulators of ion transport under basal physiologic thin film
conditions. Forskolin, via raised cellular cAMP concentrations,
induced volume secretion, not absorption as predicted from
FIGURE 8. Cyclic compressive stress/nucleotide regulation of AvSL height
of normal human AT2 cultures. Normal human AT2 cells were labeled with
Calcein Green, and AvSL was labeled with (25 l) Texas Red-labeled 70-kDa
dextran fluorophore for 30 min and then aspirated. A, control and post-UTP
addition (100 M, luminal) in AvSL heights were imaged by confocal micros-
copy in confluent normal AT2 cultures. B, confluent normal AT2 cultures were
treated without (Control) or with UTP in the absence or presence of CFTRinh-
172, and AvSL height was measured (mean  S.D.; n  3; *, p  0.05 different
from control; †, p  0.05 different from UTP treatment). C, normal human AT2
cultures were subjected to constant CCS (0 –20 cm H20) for 24 h, and AvSL
height was imaged using confocal microscopy. D, summary data for normal
AT2 cultures exposed to control (static) conditions and CCS for 24 h without
(Control) or with apyrase (Apy., 10 units/ml) treatment (means  S.D.; n  3; *,
p  0.05 different from control; †, p  0.05 different from CCS). All of the scale
bars represent 5 m. (Basolateral fluorescence occurs if minor disruption
occurs in the seal between the cell monolayer and the Transwell membrane.
This event occurs rarely and does not affect the overall integrity of the
experiment.)
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Ussing chamber studies (Fig. 2F), under these conditions (Fig. 7,
A and B). Our data suggest that the inhibition of ENaC suffi-
cient to generate electrochemical driving increases for forsko-
lin-stimulated, CFTR-mediated Cl secretion was provided by
nucleotides in the AvSL (Fig. 7B). We speculate that basal ATP
release and forskolin-induced ATP release, perhaps as a conse-
quence of secretion of surfactant granules that contain ATP,
provided the autocrine nucleotide signal for ENaC inhibition/
CFTR activation required to generate cAMP-regulated volume
secretion. Note that there has been a perplexing failure of
-agonists to therapeutically accelerate edema absorption in
respiratory distress syndrome patients (58). As one explana-
tion, inflammation may reduce -agonist signaling to account
for this therapeutic failure (59). However, our data raise the
possibility that release of extracellular ATP in RDS is sufficient
to cause -agonists to promote alveolar secretion in patients
with this syndrome, offsetting the desired therapeutic absorp-
tive response (60).
UTP also stimulated volume secretion (Fig. 8, A and B). This
result was more predictable based on Ussing chamber results
because UTP inhibited ENaC (Fig. 5A, (late)) and stimulated
CFTR-mediated Cl secretion (Fig. 5C). The UTP secretory
volume flow was more transient than forskolin. It is not yet
known whether the difference in the kinetics of volume secre-
tion between these two agonists reflects differences in the sig-
naling pathways or, conceivably, the rapid hydrolysis of the
UTP added to the alveolar surface.
Our confocal volume transport measurements suggest that
alveolar AT2 cells can, depending on conditions, absorb liquid,
secrete liquid, or maintain a homeostatic balance of liquid on
the AT2 cell surface at a steady state level. Thus, a key question
relates to what might AT2-mediated alveolar liquid transport
function be in vivo under resting/basal conditions? In vivo, the
alveolus is exposed to cyclic mechanical forces associated with
normal tidal breathing. These forces include changes in the
trans-alveolar epithelial pressure as a function of expansion of
the chest wall. Indeed, changes in transmural wall pressure in
vitro mimicking those in vivo have been shown to induce sur-
factant secretion in alveolar epithelia in culture (61) and in
human airway epithelia to increase ATP release (18). Recently,
it has been shown that increased alveolar pressures also release
ATP from the rat and mouse lung in vivo, in the context of
alveolar-endothelial signaling (62). As shown in Fig. 8C, the
application of cyclic compressive stress induced sustained liq-
uid secretion that appeared dependent on nucleotide release.
Thus, these data predict that theAT2 cells under base-line con-
ditions in vivo contribute to barrier secretion rather than
absorption.
In summary, we have generated a human AT2 monolayer
preparation that is amenable to assay by Ussing chamber and
confocal liquid transport techniques. The ion transport prop-
erties of human AT2 cells appear to differ dramatically from
human airway epithelial cells. For example, Na transport in
alveolar epithelial cells is ENaC-mediated but is positively reg-
ulated by cell cAMP signaling and not inhibited by CFTR acti-
vation. In contrast, AT2 cell anion secretion appears to be dom-
inated by CFTR, with no contribution of CaCC (TMEM16A)
channel-like activity. Nucleotide signaling appears to be impor-
tant in both respiratory epithelial regions, but the alveolus may
be dominated more by UTP/P2Y4-R signaling and perhaps
P2X4 signaling than airway epithelia. The confocal microscopy
studies of liquid transport suggest that the AT2 barrier can
respond to ambient needs, e.g. can absorb in response to the
equivalent of alveolar flooding, but can secrete in response to
addition of exogenous secretagogues. Further studies will be
required to test this hypothesis and analyze how the integrated
system, including AT1 cells, contributes to surface liquid trans-
port regulated in response to physiologic stresses in health and
in response to pathophysiologic stresses in disease.
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